Measles risk and measles-mumps-rubella vaccination timing in dermatology patients on immunosuppressive therapy
- 1Department of Dermatology, The University of Texas McGovern Medical School, Houston, Texas
- 2School of Medicine, Baylor College of Medicine, Houston, Texas
- 3Department of Dermatology, The University of Texas McGovern Medical School, Houston, Texas; Center for Clinical Studies, Webster, Texas; Correspondence to: Stephen K. Tyring, MD, PhD, MBA 6431 Fannin St, Houston, TX 77030.
Abstract
The 2025 to 2026 measles outbreak marked a significant resurgence of a vaccine-preventable disease, raising urgent public health concerns. The clinical implications of this outbreak for patients on immunosuppressive therapy, specifically in dermatology, remain poorly defined. This review addresses this gap, examining measles presentations and complications in immunosuppressed dermatology patients. We discuss diagnostic considerations specific to this population, in whom impaired humoral immunity can limit the reliability of standard testing. Finally, we propose a practical, dosing, and pharmokinetic-based framework for measles-mumps-rubella vaccination and postexposure prophylaxis decisions across commonly used dermatologic therapies. This includes specifically biologics, targeted small molecules, and conventional immunosuppressants. Current public health guidance was largely developed from oncology, transplant, and rheumatology populations, leaving dermatologists without a clear or actionable plan for their patients. This review is intended to fill that gap and serve as a quick reference tool for dermatologists navigating measles risk in the context of immunomodulatory therapy.
Related
- OP–199 Vaccination practices and safety of measles–mumps–rubella vaccine in children with food allergy
- Progress towards measles and rubella elimination in Lesotho, 2011–2025
- Population level immunity to measles and rubella 5 years before and after the MR campaign in urban Vellore, South India
- Case Study on Formulating a Multidose Lyophilized Measles-Rubella (MR) Vaccine Candidate for Local Manufacturing in Africa: Lab-Scale Results and Lessons Learned for Future Technology Transfer.
- Immunopathogenetic Features of Measles in Adults: Association of Vaccination Status with Measles-Specific IgM Levels and Cytokine Profile (IL-1β, IL-10)
BibTeX
@article{annabelshen2026measles,
title = {{Measles risk and measles-mumps-rubella vaccination timing in dermatology patients on immunosuppressive therapy}},
author = {Annabel Shen, BS and Aileen Y. Hu, BS and Kevin W. Hoffman, BS and Stephen K. Tyring, MD, PhD, MBA},
journal = {JAAD Reviews},
year = {2026},
month = oct,
doi = {10.1016/j.jdrv.2026.09.010},
url = {https://doi.org/10.1016/j.jdrv.2026.09.010},
note = {CC BY},
}
RIS
TY - JOUR
TI - Measles risk and measles-mumps-rubella vaccination timing in dermatology patients on immunosuppressive therapy
AU - Annabel Shen, BS
AU - Aileen Y. Hu, BS
AU - Kevin W. Hoffman, BS
AU - Stephen K. Tyring, MD, PhD, MBA
PY - 2026
DA - 2026/10/30
JO - JAAD Reviews
DO - 10.1016/j.jdrv.2026.09.010
UR - https://doi.org/10.1016/j.jdrv.2026.09.010
AB - The 2025 to 2026 measles outbreak marked a significant resurgence of a vaccine-preventable disease, raising urgent public health concerns. The clinical implications of this outbreak for patients on immunosuppressive therapy, specifically in dermatology, remain poorly defined. This review addresses this gap, examining measles presentations and complications in immunosuppressed dermatology patients. We discuss diagnostic considerations specific to this population, in whom impaired humoral immunity can limit the reliability of standard testing. Finally, we propose a practical, dosing, and pharmokinetic-based framework for measles-mumps-rubella vaccination and postexposure prophylaxis decisions across commonly used dermatologic therapies. This includes specifically biologics, targeted small molecules, and conventional immunosuppressants. Current public health guidance was largely developed from oncology, transplant, and rheumatology populations, leaving dermatologists without a clear or actionable plan for their patients. This review is intended to fill that gap and serve as a quick reference tool for dermatologists navigating measles risk in the context of immunomodulatory therapy.
SN - 2950-1989
ER -